Answers are grounded in this paper and cite their sources.
IntroductionSweet syndrome (acute febrile neutrophilic dermatosis) was first described by Dr. Robert Douglas Sweet in 1964 [1].The syndrome is characterized by fever, neutrophilic leukocytosis, and tender erythematous plaques.Biopsy of erythematous plaques shows a dense dermal infiltration with mature neutrophils.Response to corticosteroid treatment is generally rapid and favorable.Neurological manifestation of Sweet syndrome, termed neuro-Sweet disease, is a rare cause of aseptic meningoencephalitis.Neuro-Sweet disease also responds to corticosteroids, however, refractory cases with multiple relapses have occurred.Herein, we report a case of a patient with refractory neuro-Sweet disease, who was successfully treated with intravenous immunoglobulin (IVIG), rituximab, tocilizumab, and mycophenolate mofetil.Sweet syndrome, or acute febrile neutrophilic dermatosis, is mainly a dermatologic condition presenting with erythematous plaques; however, neutrophils infiltrate multiple systems.Neuro-Sweet disease is a neurological manifestation of Sweet syndrome and a rare cause of recurrent aseptic meningoencephalitis, which needs to be distinguished from neuro-Behçet disease.Although neuro-Sweet disease generally responds well to corticosteroids, relapsing neuro-Sweet disease is not an exceptional case.Herein, we present a case of a 51-year-old male with recurrent encephalitis followed by erythematous plaques.The patient was confirmed as Sweet syndrome based on skin biopsy and showed partial response to corticosteroids.With intravenous immunoglobulin, rituximab, tocilizumab, and mycophenolate mofetil, his neurologic symptoms were fully recovered.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: